Evidence map›Paper›PMID 41315305›Full record

ArticleScientific reports2025

In vitro drug susceptibility of Leishmania donovani from visceral leishmaniasis patients with and without HIV coinfection in Northwestern Ethiopia.

Sultan Tufa, Markos Tadele, Helina Fikre, Roman Melkamu, Arega Yeshanew, Saba Atnafu, Zemenay Mulugeta, Dagaga Kenea, Birtukan Kebede, Asrat Hailu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sultan TufaDepartment of Microbiology, Immunology and Parasitology, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Markos TadeleAnimal Health Research Program, Ethiopian Institute of Agricultural Research, Holetta, Ethiopia.
Helina FikreLeishmaniasis Research and Treatment Center (LRTC), University of Gondar, Gondar, Ethiopia.
Roman MelkamuLeishmaniasis Research and Treatment Center (LRTC), University of Gondar, Gondar, Ethiopia.
Arega YeshanewLeishmaniasis Research and Treatment Center (LRTC), University of Gondar, Gondar, Ethiopia.
Saba AtnafuLeishmaniasis Research and Treatment Center (LRTC), University of Gondar, Gondar, Ethiopia.
Zemenay MulugetaLeishmaniasis Research and Treatment Center (LRTC), University of Gondar, Gondar, Ethiopia.
Dagaga KeneaDepartment of medical laboratory science, College of Health Sciences, Arsi University, Asella, Ethiopia. Dagagakenea@gmail.com.
Birtukan KebedeDepartment of medical laboratory science, College of Health Sciences, Arsi University, Asella, Ethiopia.
Asrat HailuDepartment of Microbiology, Immunology and Parasitology, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leishmania and HIV coinfection is a major public health problem in more than 35 countries worldwide. Leishmania infection is frequently reactivated in VL and HIV coinfected patients. One of the major challenges in the management of VL/HIV coinfection is the lack of an effective drug therapy that not only resolves the first episode of VL but also prevents relapse. This study aimed to assess the in vitro drug susceptibility profile of clinical isolates of Leishmania in HIV positive and negative patients obtained during the first VL episode before treatment and during VL relapses on patients who attended LRTC of University of Gondar, Gondar, northwest Ethiopia, between January 1, 2020, and December 30, 2020. We evaluated the in vitro susceptibility to amphotericin B (AmB), paromomycin (PMM), and miltefosine (MLT) of 30 L. donovani isolates obtained from primary and relapse VL patients with and without HIV co-infection. All 30 strains of L. donovani were tested at the promastigote stage whereas, 10 randomly selected strains of L. donovani were re-tested at the amastigote stage. The mean (± SD) IC

Indexed as

Antiprotozoal AgentsCoinfectionHIV InfectionsLeishmania donovaniLeishmaniasis, VisceralAdolescentAdultAmphotericin BEthiopiaFemaleHumansMaleMiddle AgedParasitic Sensitivity TestsParomomycinPhosphorylcholineAmphotericin BAntiprotozoal AgentsmiltefosineParomomycinPhosphorylcholine

Identifiers

PMID41315305
PMCPMC12663549

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.